11 results on '"Porter, Kevin R."'
Search Results
2. Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever
- Author
-
Watts, Douglas M., Porter, Kevin R., Putvatana, Pavithat, Vasquez, Bruno, Calampa, Carlos, Hayes, Curtis G., and Halstead, Scott B.
- Published
- 1999
3. Nucleic acid (DNA) immunization as a platform for dengue vaccine development.
- Author
-
Porter, Kevin R. and Raviprakash, Kanakatte
- Subjects
- *
DENGUE , *PREVENTIVE medicine , *IMMUNIZATION , *NUCLEIC acids , *GENE expression , *DNA vaccines , *VACCINATION - Abstract
Since the early 1990s, DNA immunization has been used as a platform for developing a tetravalent dengue vaccine in response to the high priority need for protecting military personnel deployed to dengue endemic regions of the world. Several approaches have been explored ranging from naked DNA immunization to the use of live virus vectors to deliver the targeted genes for expression. Pre-clinical animal studies were largely successful in generating anti-dengue cellular and humoral immune responses that were protective either completely or partially against challenge with live dengue virus. However, Phase 1 clinical evaluation of a prototype monovalent dengue 1 DNA vaccine expressing prM and E genes revealed anti-dengue T cell IFNγ responses, but poor neutralizing antibody responses. These less than optimal results are thought to be due to poor uptake and expression of the DNA vaccine plasmids. Because DNA immunization as a vaccine platform has the advantages of ease of manufacture, flexible genetic manipulation and enhanced stability, efforts continue to improve the immunogenicity of these vaccines using a variety of methods. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
4. Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine
- Author
-
Porter, Kevin R., Ewing, Daniel, Chen, Lan, Wu, Shuenn-Jue, Hayes, Curtis G., Ferrari, Marilyn, Teneza-Mora, Nimfa, and Raviprakash, Kanakatte
- Subjects
- *
IMMUNE response , *DRUG efficacy , *LIPIDS , *MENINGOCOCCAL vaccines , *DNA vaccines , *CLINICAL trials , *IMMUNIZATION , *BIOLOGICAL assay , *PRIMATES as laboratory animals - Abstract
Abstract: A prototype dengue-1 DNA vaccine was shown to be safe and immunogenic in a previous Phase 1 clinical trial. Anti-dengue-1 neutralizing antibody responses were detectable only in the group of volunteers receiving the high dose of nonadjuvanted vaccine and the antibody titers were low. Vaxfectin®, a lipid-based adjuvant, enhances the immunogenicity of DNA vaccines. We conducted a nonhuman primate study to evaluate the effect of Vaxfectin® on the immunogenicity of a tetravalent dengue DNA vaccine. Animals were immunized on days 0, 28 and 84, with each immunization consisting of 3mg of Vaxfectin®-adjuvanted tetravalent dengue DNA vaccine. The use of Vaxfectin® resulted in a significant increase in anti-dengue neutralizing antibody responses against dengue-1, -3 and -4. There was little to no effect on T cell responses as measured by interferon gamma ELISPOT assay. Animals immunized with the Vaxfectin®-formulated tetravalent DNA vaccine showed significant protection against live dengue-2 virus challenge compared to control animals (0.75 mean days of viremia vs 3.3 days). Animals vaccinated with nonadjuvanted DNA had a mean 2.0 days of viremia. These results support further evaluation of the Vaxfectin®-adjuvanted tetravalent dengue DNA vaccine in a Phase 1 clinical trial. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
5. Development of dengue DNA vaccines
- Author
-
Danko, Janine R., Beckett, Charmagne G., and Porter, Kevin R.
- Subjects
- *
DNA vaccines , *DENGUE , *CELLULAR immunity , *CLINICAL trials , *VACCINATION - Abstract
Abstract: Vaccination with plasmid DNA against infectious pathogens including dengue is an active area of investigation. By design, DNA vaccines are able to elicit both antibody responses and cellular immune responses capable of mediating long-term protection. Great technical improvements have been made in dengue DNA vaccine constructs and trials are underway to study these in the clinic. The scope of this review is to highlight the rich history of this vaccine platform and the work in dengue DNA vaccines accomplished by scientists at the Naval Medical Research Center. This work resulted in the only dengue DNA vaccine tested in a clinical trial to date. Additional advancements paving the road ahead in dengue DNA vaccine development are also discussed. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
6. Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys
- Author
-
Maves, Ryan C., Oré, Roger M. Castillo, Porter, Kevin R., and Kochel, Tadeusz J.
- Subjects
- *
VIRAL vaccines , *DRUG efficacy , *PSORALENS , *DENGUE viruses , *AOTUS nancymaae , *PYRIMIDINES , *CROSSLINKED polymers , *LABORATORY monkeys - Abstract
Abstract: Psoralens are photoreactive compounds that cross-link pyrimidines after exposure to UVA radiation. In this experiment, we tested the protective efficacy of a psoralen-inactivated dengue vaccine candidate in non-human primates. Two groups of 7 Aotus nancymaae monkeys received either 10ng per dose of inactivated DENV1 plus alum adjuvant or alum alone (controls). Doses were injected intradermally on days 0, 14, and 28. Monkeys then received a challenge inoculation of 1.1×104 PFUs of WestPac 74 DENV-1 on day 132. At 62 days, only 1/7 vaccinated monkeys had detectable IgM, but IgG and neutralizing antibody remained detectable in 7/7. No IgM, IgG, or neutralizing antibody was detectable in control monkeys. DENV-1 viremia was detected after challenge in 3/7 vaccinated monkeys and 5/6 control monkeys (with one removed due to pregnancy) (p =0.27), but days of viremia were reduced from 3.67 days/animal among controls to 0.71 days/animal among vaccinated monkeys (p =0.051). Psoralen-inactivated DENV1 is immunogenic in Aotus nancymaae with a trend towards a reduction in days of viremia following experimental challenge. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
7. Comparison of purified psoralen-inactivated and formalin-inactivated dengue vaccines in mice and nonhuman primates.
- Author
-
Sundaram, Appavu K., Ewing, Daniel, Blevins, Maria, Liang, Zhaodong, Sink, Sandy, Lassan, Josef, Raviprakash, Kanakatte, Defang, Gabriel, Williams, Maya, Porter, Kevin R., and Sanders, John W.
- Subjects
- *
DENGUE viruses , *DENGUE , *ARBOVIRUS diseases , *VIRAL vaccines , *VACCINES , *PRIMATES , *VACCINE effectiveness - Abstract
• Two-step purification of Dengue virus using Chromatographic methods. • Psoralen-inactivation of Dengue virus. • Evaluation of psoralen-inactivated Dengue virus vaccines in mice. • Evaluation of psoralen-inactivated Dengue virus vaccines in nonhuman primates. Dengue fever, caused by dengue viruses (DENV 1–4) is a leading cause of illness and death in the tropics and subtropics. Therefore, an effective vaccine is urgently needed. Currently, the only available licensed dengue vaccine is a chimeric live attenuated vaccine that shows varying efficacy depending on serotype, age and baseline DENV serostatus. Accordingly, a dengue vaccine that is effective in seronegative adults, children of all ages and in immunocompromised individuals is still needed. We are currently researching the use of psoralen to develop an inactivated tetravalent dengue vaccine. Unlike traditional formalin inactivation, psoralen inactivates pathogens at the nucleic acid level, potentially preserving envelope protein epitopes important for protective anti-dengue immune responses. We prepared highly purified monovalent vaccine lots of formalin- and psoralen-inactivated DENV 1–4, using Capto DeVirS and Capto Core 700 resin based column chromatography. Tetravalent psoralen-inactivated vaccines (PsIV) and formalin-inactivated vaccines (FIV) were prepared by combining the four monovalent vaccines. Mice were immunized with either a low or high dose of PsIV or FIV to evaluate the immunogenicity of monovalent as well as tetravalent formulations of each inactivation method. In general, the monovalent and tetravalent PsIVs elicited equivalent or higher titers of neutralizing antibodies to DENV than the FIV dengue vaccines and this response was dose dependent. The immunogenicity of tetravalent dengue PsIVs and FIVs were also evaluated in nonhuman primates (NHPs). Consistent with what was observed in mice, significantly higher neutralizing antibody titers for each dengue serotype were observed in the NHPs vaccinated with the tetravalent dengue PsIV compared to those vaccinated with the tetravalent dengue FIV, indicative of the importance of envelope protein epitope preservation during psoralen inactivation of DENV. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. Enhanced immunogenicity and protective efficacy of a tetravalent dengue DNA vaccine using electroporation and intradermal delivery.
- Author
-
Williams, Maya, Ewing, Dan, Blevins, Maria, Sun, Peifang, Sundaram, Appavu K., Raviprakash, Kanakatte S., Porter, Kevin R., and Sanders, John W.
- Subjects
- *
ELECTROPORATION , *DNA vaccines , *HUMORAL immunity , *DENGUE , *B cells , *INTRAMUSCULAR injections - Abstract
Phase 1 clinical trials with a DNA vaccine for dengue demonstrated that the vaccine is safe and well tolerated, however it produced less than optimal humoral immune responses. To determine if the immunogenicity of the tetravalent dengue DNA vaccine could be enhanced, we explored alternate, yet to be tested, methods of vaccine administration in non-human primates. Animals were vaccinated on days 0, 28 and 91 with either a low (1 mg) or high (5 mg) dose of vaccine by the intradermal or intramuscular route, using either needle-free injection or electroporation devices. Neutralizing antibody, IFN-γ T cell and memory B cell responses were compared to a high dose group vaccinated with a needle-free intramuscular injection delivery device similar to what had been used in previous preclinical and clinical studies. All previously untested vaccination methodologies elicited improved immune responses compared to the high dose needle-free intramuscular injection delivery group. The highest neutralizing antibody responses were observed in the group that was vaccinated with the high dose formulation via intradermal electroporation. The highest IFN-γ T cell responses were also observed in the high dose intradermal electroporation group and the CD8+ T cells were the dominant contributors for the IFNγ response. Memory B cells were detected for all four serotypes. More than a year after vaccination, groups were challenged with dengue-1 virus. Both the low and high dose intradermal electroporation groups had significantly fewer days of dengue-1 virus RNAemia compared to the control group. The results from this study demonstrate that using either an electroporation device and/or the intradermal route of delivery increases the immune response generated by this vaccine in non-human primates and should be explored in humans. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
9. NK cell degranulation as a marker for measuring antibody-dependent cytotoxicity in neutralizing and non-neutralizing human sera from dengue patients.
- Author
-
Sun, Peifang, Morrison, Brian J., Beckett, Charmagne G., Liang, Zhaodong, Nagabhushana, Nishith, Li, An, Porter, Kevin R., and Williams, Maya
- Subjects
- *
CELL-mediated cytotoxicity , *KILLER cells , *DENGUE , *IMMUNE response , *BIOMARKERS , *GENE expression , *PATIENTS - Abstract
The study assessed antibody-dependent NK cell degranulation, a biomarker relevant to antibody-dependent cell cytotoxicity (ADCC), to analyze dengue immune sera. We first determined binding intensity of patient sera to the surface of DENV-infected cells and examined the types of antigens expressed on infected cells. Antigens from pre-membrane (PreM) and envelope (E), but not from NS proteins were detected on the surface of infected cells. After adding NK cells to infected target cells previously treated with patient sera, rapid NK cell degranulation was observed. Non-neutralizing patient sera generated comparable NK cell degranulation as that of neutralizing sera, suggesting ADCC may be a protective mechanism apart from Ab neutralization. The level of NK cell degranulation varied dramatically among human individuals and was associated with the level of CD16 expression on NK cells, informing on the complexity of ADCC among human population. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
10. Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial
- Author
-
Beckett, Charmagne G., Tjaden, Jeffrey, Burgess, Timothy, Danko, Janine R., Tamminga, Cindy, Simmons, Monika, Wu, Shuenn-Jue, Sun, Peifang, Kochel, Tadeusz, Raviprakash, Kanakatte, Hayes, Curtis G., and Porter, Kevin R.
- Subjects
- *
DENGUE , *DNA vaccines , *CLINICAL trials , *SEROTYPES , *IMMUNOGENETICS , *BIOLOGICAL membranes , *VIRAL envelopes , *PLASMID genetics , *GENETIC vectors , *INTRAMUSCULAR injections , *VACCINATION - Abstract
Abstract: Candidate dengue DNA vaccine constructs for each dengue serotype were developed by incorporating pre-membrane and envelope genes into a plasmid vector. A Phase 1 clinical trial was performed using the dengue virus serotype-1 (DENV-1) vaccine construct (D1ME100). The study was an open-label, dose-escalation, safety and immunogenicity trial involving 22 healthy flavivirus-naïve adults assigned to one of two groups. Each group received three intramuscular injections (0, 1, and 5 months) of either a high dose (5.0mg, n =12) or a low dose (1.0mg, n =10) DNA vaccine using the needle-free Biojector® 2000. The most commonly reported solicited signs and symptoms were local mild pain or tenderness (10/22, 45%), local mild swelling (6/22, 27%), muscle pain (6/22, 27%) and fatigue (6/22, 27%). Five subjects (41.6%) in the high dose group and none in the low dose group developed detectable anti-dengue neutralizing antibodies. T-cell IFN gamma responses were detected in 50% (4/8) and 83.3% (10/12) of subjects in the low and high dose groups, respectively. The safety profile of the DENV-1 DNA vaccine is acceptable at both doses administered in the study. These results demonstrate a favorable reactogenicity and safety profile of the first in human evaluation of a DENV-1 DNA vaccine. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
11. Evaluation of immunity and protective efficacy of a dengue-3 premembrane and envelope DNA vaccine in Aotus nancymae monkeys
- Author
-
Blair, Patrick J., Kochel, Tadeusz J., Raviprakash, Kanakatte, Guevara, Carolina, Salazar, Milagros, Wu, Shuenn-Jue, Olson, James G., and Porter, Kevin R.
- Subjects
- *
NUCLEIC acids , *DNA vaccines , *PREVENTIVE medicine , *VACCINATION - Abstract
Abstract: A dengue (DEN) virus type 3 DNA vaccine expressing pre-membrane and envelope genes was tested for immunogenicity and protective efficacy in Aotus monkeys. Five of six vaccinated animals demonstrated moderate DEN-specific antibody responses as measured by ELISA and virus neutralization in vitro. By contrast, none of the six control animals developed detectable anti-DEN antibodies. When five vaccinated animals were challenged with live DEN-3 virus and viremia determined by PCR amplification of viral RNA in serum samples, one animal was completely protected and two were partially protected as indicated by a decrease in mean days of viremia. The results demonstrate the ability of the DEN-3 DNA vaccine to elicit a neutralizing antibody response and to partially protect against live virus challenge. These findings support the inclusion of this construct in a tetravalent DNA vaccine. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.